Can a new biologic calm airway inflammation in COPD?

NCT ID NCT07730281

Not yet recruiting Disease control Sponsor: Prana Therapies Inc Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether an experimental drug called PRA-216 can safely reduce airway inflammation in people with moderate to severe COPD who have a specific type of inflammation (type 2). Participants will receive either PRA-216 or a placebo, and researchers will monitor side effects and measure changes in a biomarker of lung inflammation. The study aims to see if PRA-216 is a promising treatment for this common lung disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental biologic drug called PRA-216
What this could lead to: If successful, PRA-216 could offer a new treatment option for COPD patients with type 2 inflammation, potentially reducing flare-ups and improving lung function.
What could go wrong: This is an early phase 2 trial with only 40 participants, so results may not apply to all COPD patients. The drug's safety and effectiveness are still unproven, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

More trials for these conditions

Other studies related to the condition(s) this trial covers.